Back to Search
Start Over
The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.
- Source :
- Human Genomics; 12/28/2016, Vol. 10, p1-2, 2p
- Publication Year :
- 2016
-
Abstract
- Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutantenriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel Kras mutations (A11V, V14I). [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14739542
- Volume :
- 10
- Database :
- Complementary Index
- Journal :
- Human Genomics
- Publication Type :
- Academic Journal
- Accession number :
- 120702047
- Full Text :
- https://doi.org/10.1186/s40246-016-0096-9